Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1986 1
1988 2
1991 5
1992 6
1993 5
1994 3
1995 1
1996 2
1997 5
1998 9
1999 13
2000 37
2001 47
2002 60
2003 54
2004 61
2005 103
2006 85
2007 93
2008 78
2009 88
2010 91
2011 139
2012 173
2013 233
2014 321
2015 262
2016 242
2017 275
2018 283
2019 131
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

2,618 results
Results by year
Filters applied: . Clear all
Page 1
Bictegravir
Spagnuolo V, et al. Curr Opin HIV AIDS 2018 - Review. PMID 29746268
Results of the phase 3 GS-US-380-1489 and GS-US-380-1490 clinical trials showed that the coformulation B/F/TAF is not inferior to the recommended DTG-containing regimens in naïve subjects. ...
Results of the phase 3 GS-US-380-1489 and GS-US-380-1490 clinical trials showed that the coformulation B/F/TAF is not inferior to the …
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, et al. Lancet 2019 - Clinical Trial. PMID 30420123
METHODS: We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and GEMINI-2. ...
METHODS: We conducted two identically designed, multicentre, double-blind, randomised, non-inferiority, phase 3 trials: GEMINI-1 and …
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Llibre JM, et al. Lancet 2018 - Clinical Trial. PMID 29310899
We aimed to investigate this two-drug regimen in a phase 3 study. METHODS: We identically designed SWORD-1 and SWORD-2, which were open-label, parallel-group, multicentre, phase 3, randomised, non-inferiority studies in 12 countries evaluating efficacy and safety of once-daily dolutegravir 50 mg plus rilpivirine 25 mg versus current ART regimen (CAR). ...More participants taking dolutegravir-rilpivirine (17 [3%]) reported adverse events leading to withdrawal than did participants taking CAR (three [<1%]). ...
We aimed to investigate this two-drug regimen in a phase 3 study. METHODS: We identically designed SWORD-1 and SWORD-2, which were op …
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Westhovens R. Rheumatology (Oxford) 2019 - Review. PMID 30806706 Free PMC article.
New compounds are under investigation that are more selective for Janus kinase 1 or Janus kinase 3. Phase II results for filgotinib, upadacitinib, peficitinib and decernotinib are reviewed showing almost consistently a fast dose-dependent clinical improvement similar to already approved drugs tofacitinib and baricitinib. ...
New compounds are under investigation that are more selective for Janus kinase 1 or Janus kinase 3. Phase II results for filgo …
Resistance-gene-directed discovery of a natural-product herbicide with a new mode of action
Yan Y, et al. Nature 2018. PMID 29995859 Free PMC article.
Bioactive natural products have evolved to inhibit specific cellular targets and have served as lead molecules for health and agricultural applications for the past century(1-3). ...
Bioactive natural products have evolved to inhibit specific cellular targets and have served as lead molecules for health and agricultural a …
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC, et al. Lancet 2018 - Clinical Trial. PMID 29908670
METHODS: We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs). ...
METHODS: We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or o …
2,618 results
Jump to page
Feedback